1. APA. Diagnostic and Statistical Manual of Mental Disorders . 5th edition. American Psychiatric Publishing. 2013:490-497.
2. Fleming MF, Smith MJ, Oslakovic E, et al. Phosphatidylethanol detects moderate-to-heavy alcohol use in liver transplant recipients. Alcohol Clin Exp Res . 2017;41:857-862.
3. National Institute on Alcohol Abuse and Alcoholism. Drinking levels defined. Accessed November 12, 2021. www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking
4. Herreros-Villanueva M, Hijona E, Bañales JM, et al. Alcohol consumption on pancreatic diseases. World J Gastroenterol . 2013;19:638-647.
5. Rocco A, Compare D, Angrisani D, et al. Alcoholic disease: liver and beyond. World J Gastroenterol . 2014;20:14652-14659.
6. Gardner JD, Mouton AJ. Alcohol effects on cardiac function. Compr Physiol . 2015;5:791-802.
7. Sebastiani G, Borrás-Novell C, Casanova MA, et al. The effects of alcohol and drugs of abuse on maternal nutritional profile during pregnancy. Nutrients . 2018;10:1008.
8. Rehm J, Anderson P, Manthey J, et al. Alcohol use disorders in primary health care: what do we know and where do we go? Alcohol Alcohol . 2016;51:422-427. doi: 10.1093/alcalc/agv127
9. ASAM. Caring for patients during the COVID-19 pandemic. Accessed November 12, 2021. www.asam.org/docs/default-source/covid-19/acute-care_062620.pdf?sfvrsn=e66d54c2_10
10. Miller PM, Thomas SE, Mallin R. Patient attitudes towards self-report and biomarker alcohol screening by primary care physicians. Alcohol Alcohol . 2006;41:306-310. doi: 10.1093/alcalc/agl022
11. Zoorob R, Snell H, Kihlberg C, et al. Screening and brief intervention for risky alcohol use. Curr Probl Pediatr Adolesc Health Care . 2014;44:82-87.
12. Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a single-question alcohol screening test. J Gen Intern Med . 2009;24:783-788.
13. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA . 1984;252:1905-1907.
14. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol . 1989;160:863-868.
15. Cherpitel CJ. A brief screening instrument for problem drinking in the emergency room: the RAPS4. Rapid Alcohol Problems Screen. J Stud Alcohol . 2000;61:447-449.
16. WHO. AUDIT: The alcohol use identification test. Accessed November 14, 2021. http://apps.who.int/iris/bitstream/handle/10665/67205/WHO_MSD_MSB_01.6a.pdf?sequence=1
17. Westermeyer J, Yargic I, Thuras P. Michigan assessment-screening test for alcohol and drugs (MAST/AD): evaluation in a clinical sample. Am J Addict . 2004;13:151-162.
18. Powers JS, Spickard A. Michigan Alcoholism Screening Test to diagnose early alcoholism in a general practice. South Med J . 1984;77:852-856.
19. NIH. Treatment for alcohol problems: finding and getting help. Accessed November 12, 2021. www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help
20. Kitchens JM. Does this patient have an alcohol problem? JAMA . 1994;272:1782-1787.
21. Kummer N, Lambert WE, Samyn N, et al. Alternative sampling strategies for the assessment of alcohol intake of living persons. Clin Biochem . 2016;49:1078-1091.
22. Ulwelling W, Smith K. The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines. J Forensic Sci . 2018;63:1634-1640.
23. Mundle G, Ackermann K, Munkes J, et al. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate‐deficient transferrin, gamma‐glutamyltransferase and mean corpuscular volume. Alcohol Alcohol . 1999;34:760-766.
24. Neumann T, Spies C. Use of biomarkers for alcohol use disorders in clinical practice. Addiction . 2003;98(suppl 2):81-91.
25. Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol . 2014;20:11684-11699.
26. Helander A. Biological markers of alcohol use and abuse in theory and practice. In: Agarwal DP, Seitz HK, eds. Alcohol in Health and Disease. Marcel Dekker. 2001:177-205.
27. Stewart SH, Koch DG, Burgess DM, et al. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol Clin Exp Res . 2013;37:150-155.
28. Helander A, Dahl H. Urinary tract infection: a risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. Clin Chem . 2005;51:1728-1730.
29. Ghosh S, Jain R, Jhanjee S, et al. Alcohol biomarkers and their relevance in detection of alcohol consumption in clinical settings. Accessed November 12, 2021. https://www.clinmedjournals.org/articles/iasar/international-archives-of-substance-abuse-and-rehabilitation-iasar-1-002.php?jid=iasar
30. Borucki K, Dierkes J, Wartberg J, et al. In heavy drinkers, fatty acid ethyl esters remain elevated for up to 99 hours. Alcohol Clin Exp Res . 2007;31:423-427.
31. Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol . 2007;12:81-84.
32. Choe YM, Lee BC, Choi IG, et al. Combination of the CAGE and serum gamma-glutamyl transferase: an effective screening tool for alcohol use disorder and alcohol dependence. Neuropsychiatr Dis Treat . 2019 31;15:1507-1515.
33. Niemelä O. Biomarkers in alcoholism. Clin Chim Acta . 2007;377:39-49.
34. Kauffmann T, Evans DS. Macrocytosis. Accessed November 12, 2021. https://www.ncbi.nlm.nih.gov/books/NBK560908/
35. Maenhout TM, De Buyzere ML, Delanghe JR. Non-oxidative ethanol metabolites as a measure of alcohol intake. Clin Chim Acta . 2013;415:322-329.
36. Solomons HD. Carbohydrate deficient transferrin and alcoholism. Germs . 2012;2:75-78.
37. Allen JP, Wurst FM, Thon N, et al. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl . 2013;19:369-376.
38. Bortolotti F, De Paoli G, Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J Chromatogr B Analyt Technol Biomed Life Sci . 2006;841:96-109.
39. Hannuksela ML, Liisanantti MK, Nissinen AE, et al. Biochemical markers of alcoholism. Clin Chem Lab Med . 2007;45:953-961.
40. Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem . 2001;47:13-27.
41. Cabarcos P, Hassan HM, Tabernero MJ, et al. Analysis of ethyl glucuronide in hair samples by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Appl Toxicol . 2013;33:638-643.
42. Piano MR, Mazzuco A, Kang M, et al. Binge drinking episodes in young adults: how should we measure them in a research setting? J Stud Alcohol Drugs . 2017;78:502-511.
43. Adinoff B, Bone GH, Linnoila M. Acute ethanol poisoning and the ethanol withdrawal syndrome. Med Toxicol Adverse Drug Exp . 1988;3:172-196.
44. Cabezas J, Lucey MR, Bataller R. Biomarkers for monitoring alcohol use. Clin Liver Dis (Hoboken) . 2016;8:59-63.
45. Wurst FM, Alling C, Aradottir S, et al. Emerging biomarkers: new directions and clinical applications. Alcohol Clin Exp Res . 2005;29:465-473.
46. Helander A, Péter O, Zheng Y. Monitoring of the alcohol biomarkers PEth, CDT and EtG/EtS in an outpatient treatment setting. Alcohol Alcohol . 2012;47:552-557.
47. Helander A, Böttcher M, Fehr C, et al. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol . 2009;44:55-61.
48. Jatlow P, O’Malley SS. Clinical (nonforensic) application of ethyl glucuronide measurement: are we ready? Alcohol Clin Exp Res . 2010;34:968-975.
49. Jatlow PI, Agro A, Wu R, et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res . 2014;38:2056-2065.
50. Gonzalo P, Radenne S, Gonzalo S. Biomarkers of chronic alcohol misuse. Curr Biomark Find . 2014;4:9-22.
51. Bornhorst JA, Mbughuni MM. Alcohol biomarkers: clinical issues and analytical methods. In: Critical Issues in Alcohol and Drugs of Abuse Testing . 2nd ed. Academic Press. 2019:25-42.
52. Soderberg BL, Salem RO, Best CA, et al. Fatty acid ethyl esters. Ethanol metabolites that reflect ethanol intake. Am J Clin Pathol . 2003;119(suppl):S94-S99.
53. Cheng CT, Ostrea EM Jr, Alviedo JN, et al. Fatty acid ethyl esters in meconium: a biomarker of fetal alcohol exposure and effect. Exp Biol Med (Maywood) . 2021;246:380-386.
54. Andresen-Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int . 2017;30:611-620.
55. Viel G, Boscolo-Berto R, Cecchetto G, et al. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci . 2012;13:14788-14812.
56. Gnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res . 2012;36:1507-1511.
57. Aradóttir S, Moller K, Alling C. Phosphatidylethanol formation and degradation in human and rat blood. Alcohol Alcohol . 2004;39:8-13.
58. Varga A, Alling C. Formation of phosphatidylethanol in vitro in red blood cells from healthy volunteers and chronic alcoholics. J Lab Clin Med . 2002;140:79-83.
59. Javors MA, Hill-Kapturczak N, Roache JD, et al. Characterization of the pharmacokinetics of phosphatidylethanol 16:0/18:1 and 16:0/18:2 in human whole blood after alcohol consumption in a clinical laboratory study. Alcohol Clin Exp Res . 2016;40:1228-1234.
60. Schröck A, Pfäffli M, König S, et al. Application of phosphatidylethanol (PEth) in whole blood in comparison to ethyl glucuronide in hair (hEtG) in driving aptitude assessment (DAA). Int J Legal Med . 2016;130:1527-1533.
61. Stewart SH, Koch DG, Willner IR, et al. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res . 2014;38:1706-1711.
62. Nanau RM, Neuman MG. Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions. Biomolecules . 2015 29;5:1339-1385.
63. Hill-Kapturczak N, Dougherty DM, Roache JD, et al. Phosphatidylethanol homologs in blood as biomarkers for the time frame and amount of recent alcohol consumption. In: Preedy VR (ed) Neuroscience of Alcohol . Academic Press; 2019:567-576.
64. Jain J, Evans JL, Briceño A, et al. Comparison of phosphatidylethanol results to self-reported alcohol consumption among young injection drug users. Alcohol Alcohol . 2014;49:520-524.
65. Schröck A, Wurst FM, Thon N, et al. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test - C (AUDIT-C). Drug Alcohol Depend . 2017;178:80-86.
66. McDonnell MG, Skalisky J, Leickly E, et al. Pilot investigation of a phosphatidylethanol-based contingency management intervention targeting alcohol use. Psychol Addict Behav . 2017;31:608-613.
67. Asrani SK, Trotter J, Lake J, et al. Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis. Liver Transpl . 2020;26:127-140.
68. WHO. International Guide for Monitoring Alcohol Consumption and Harm. 2000. Accessed November 12, 2021. http://apps.who.int/iris/bitstream/handle/10665/66529/WHO_MSD_MSB_00.4.pdf?sequence=1
